Send Message
View as an RSS Feed
  • At $28K a vial, Questcor's (QCOR) Acthar has propelled shares to huge gains. QCOR bought the drug for $100K in 2001, planning to produce it only to treat infantile spasms. But thanks to aggressive marketing, it's now being prescribed for MS, arthritis, and kidney disease. Aetna's (AET) decision to limit off-label treatments has hit shares, but it's not clear any viable alternatives are on the horizon. (NYT[View news story]
    Correction: a vial of Acthar gel contains enough for five injections, not one. Still expensive, but the results justify the $$$$'s.
    Dec 31, 2012. 09:13 AM | Likes Like |Link to Comment
  • Questcor III: After The Earnings  [View article]
    Most thorough reporting. The QCOR investing community owes Michael Fuller a debt of gratitude. Might I add that the patient videos on You Tube are mostly laudatory and worth a gander.
    Oct 30, 2012. 12:40 PM | 3 Likes Like |Link to Comment
  • Questcor (QCOR): Q3 EPS of $0.91 beats by $0.14. Revenue of $140.3M beats by $11M. (PR[View news story]
    sigh of relief!
    Oct 23, 2012. 07:37 PM | Likes Like |Link to Comment
  • A.P. Pharma: Refiling Of NDA For APF530 Could Cause Price Strength  [View article]
    Couple of points. First, there are supposed to be 300,000,000 shares outstanding. That's called dillution!

    Second, what if a physician wants to stop APF530 for any reason? a pill a day has some advantages. There are advantages and disadvantages to both approaches and I am not a medical person, just a droid looking for answers.

    I have purchased some APPA. This is a company with some history; wish I knew more about them and what made them into what is essentially a penny stock looking at the footlights.
    Oct 16, 2012. 10:21 PM | Likes Like |Link to Comment